Global COVID-19 Traditional Chinese Medicine Treatment Market, By Severity (Early Stage, Advance Stage, Critical Stage, Recovery Stage), Treatment (Primary, Secondary, Others), Compounds (Angong Niuhuang, Zixue, Huoxiang Zhengqi, Jinhua Qinggan, Xiyanping, Xuebijing, Reduning, Xingnaojing, Others), Dosage (Oral, Parenteral, Others), End-Users (Hospitals, Departmental Store, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global COVID-19 Traditional Chinese Medicine Treatment Market
Global COVID-19 traditional Chinese medicine treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR 12.50% in the above-mentioned research forecast period. Emerging markets and huge investments in research and development are the factors responsible for the growth of this market.
However, the rising demand for traditional Chinese medicines from developing economies also boost up the market growth. Moreover, rising cases of coronavirus infection and off the label drug usage for treatment provides lucrative opportunities for market growth. But, disputes about the safety & efficiency of traditional Chinese medicines may hamper the global COVID-19 traditional Chinese medicine treatment market.
Traditional Chinese medicine is the source of medicine that can be directly used against coronavirus infected patients. The reason behind the use of TCM also proved to be effective for patients with the severe acute respiratory syndrome (SARS) during the SARS epidemic. Chinese medicines are extracted from plant sources to treat severe respiratory diseases. In East Asian countries for thousands of years, it has been widely used to treat various diseases. In western countries, Chinese medicine as a form of complementary medicine is increasingly accepted.
According to the studies, the patients showed that the main clinical symptoms of COVID-19 patients are fever (88.5%), cough (68.6%), myalgia or fatigue (35.8%), expectoration (28.2%), and dyspnea (21.9%). The minor symptoms include headache or dizziness (12.1%), diarrhea (4.8%), and nausea and vomiting (3.9%).
This COVID-19 traditional Chinese medicine treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global COVID-19 Traditional Chinese Medicine Treatment Market Scope and Market Size
The COVID-19 traditional Chinese medicine treatment market is segmented on the basis of severity, treatment, compounds, dosage, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of severity, the COVID-19 traditional Chinese medicine treatment market is segmented into early stage, advance stage, critical stage and recovery stage.
- On the basis of treatment, the COVID-19 traditional Chinese medicine treatment market is segmented into primary, secondary and others.
- On the basis of compounds, the COVID-19 traditional Chinese medicine treatment market is segmented into angong niuhuang, zixue, huoxiang zhengqi, jinhua qinggan, xiyanping, xuebijing, reduning, xingnaojing and others.
- On the basis of dosage, the COVID-19 traditional Chinese medicine treatment market is segmented into oral, parenteral and others.
- On the basis of end-users, the COVID-19 traditional Chinese medicine treatment market is segmented into hospitals, specialty clinics and others.
- On the basis of distribution channel, the COVID-19 traditional Chinese medicine treatment market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.
COVID-19 Traditional Chinese Medicine Treatment Market Country Level Analysis
COVID-19 traditional Chinese medicine treatment market is analysed and market size information is provided by country, severity, treatment, compound, dosage, end-users and distribution channel as referenced above.
The countries covered in the COVID-19 traditional Chinese medicine treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, Asia-Pacific accounts the largest market share due to the presence of number of traditional medicine key players and increased research and development. North America is expected to account for the largest market share over coming years for the COVID-19 traditional Chinese medicine treatment market due to increased advancement in the technology as well as growing healthcare expenditure and rising awareness program.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
COVID-19 traditional Chinese medicine treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and COVID-19 Traditional Chinese Medicine Treatment Market Share Analysis
COVID-19 traditional Chinese medicine treatment market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to COVID-19 traditional Chinese medicine treatment market.
The major players covered in the COVID-19 traditional Chinese medicine treatment market are Shijiazhuang Yiling Pharmaceutical Co,Ltd., Tianjin Chase Sun Pharmaceutical Co., Ltd., China Traditional Chinese Medicine Holdings Co. Limited., Guangzhou Pharmaceutical Holdings Limited., Yunnan Baiyao., Xiamen Traditional Chinese Medicine Co., Ltd., KPC Pharmaceuticals, Inc., Aroma, Beijing Tong Ren Tang Chinese Medicine Co. Ltd., China SXT Pharmaceuticals, Inc., Jumpcan., Kangmei Pharmaceutical Co., Ltd., Merro Pharmaceutical Co.,Ltd., among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-